INZY (Inozyme Pharma) EBIT per Share : $-1.46 (TTM As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Inozyme Pharma EBIT per Share?

Inozyme Pharma's EBIT per Share for the three months ended in Sep. 2024 was $-0.37. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $-1.46.

During the past 3 years, the average EBIT per Share Growth Rate was 34.40% per year. During the past 5 years, the average EBIT per Share Growth Rate was -9.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Inozyme Pharma's EBIT per Share or its related term are showing as below:

INZY' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -46.4 Med: -9.8 Max: 34.4
Current: 34.4

During the past 6 years, the highest 3-Year average EBIT per Share Growth Rate of Inozyme Pharma was 34.40% per year. The lowest was -46.40% per year. And the median was -9.80% per year.

INZY's 3-Year EBIT Growth Rate is ranked better than
84.72% of 1250 companies
in the Biotechnology industry
Industry Median: 2.8 vs INZY: 34.40

Inozyme Pharma's EBIT for the three months ended in Sep. 2024 was $-23.15 Mil.

Inozyme Pharma EBIT per Share Historical Data

The historical data trend for Inozyme Pharma's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inozyme Pharma EBIT per Share Chart

Inozyme Pharma Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-1.37

-5.17

-2.41

-1.77

-1.31

Inozyme Pharma Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT per Share	Get a 7-Day Free Trial															-0.28	-0.33	-0.36	-0.41	-0.37

Inozyme Pharma EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Inozyme Pharma's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-67.836	/	51.839
=	-1.31

Inozyme Pharma's EBIT per Share for the quarter that ended in Sep. 2024 is calculated as

	EBIT per Share		(Q: Sep. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-23.154	/	63.277
=	-0.37

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.46

Inozyme Pharma (NAS:INZY) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Inozyme Pharma EBIT per Share Related Terms

Thank you for viewing the detailed overview of Inozyme Pharma's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Inozyme Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inozyme Pharma Inc (NAS:INZY) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

321 Summer Street, Suite 400, Boston, MA, USA, 02210

Website

https://www.inozyme.com

Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.

Executives

Douglas A Treco	director	87 CAMBRIDGEPARK DRIVE, C/O RA PHARMACEUTICALS, INC., CAMBRIDGE MA 02140
Robert Lorne Hopfner	director, 10 percent owner	C/O BAY CITY CAPITAL, LLC, 750 BATTERY STREET, SUITE 400, SAN FRANCISCO CA 94111
Pivotal Bioventure Partners Fund I G.p., L.p.	director	501 SECOND STREET, SUITE 200, SAN FRANCISCO CA 94107
Pivotal Bioventure Partners Fund I U.g.p. Ltd	director	501 SECOND STREET, SUITE 200, SAN FRANCISCO CA 94107
Pivotal Bioventure Partners Fund I, L.p.	director	501 SECOND STREET, SUITE 200, SAN FRANCISCO CA 94107
Matthew Winton	officer: COO	C/O INOZYME PHARMA, INC., 321 SUMMER STREET, SUITE 400, BOSTON MA 02210
Sanjay Subramanian	officer: SVP, CFO	5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Henric Bjorn Bjarke	officer: See Remarks	ONE UNIVERSITY SQUARE DRIVE, SUITE 280, PRINCETON NJ 08540
Axel Bolte	director, 10 percent owner, officer: See Remarks	PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Longitude Capital Partners Iii, Llc	10 percent owner	800 EL CAMINO, SUITE 220, MENLO PARK CA 94025
Inozyme Pharma, Inc.	director	321 SUMMER STREET, SUITE 400, BOSTON MA 02210
Stephen J. Dipalma	officer: Interim CFO	C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE MA 02139
Deborah Wenkert	officer: SVP, CMO	C/O INOZYME PHARMA, INC., 321 SUMMER STREET, SUITE 400, BOSTON MA 02210
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Scott D Sandell	10 percent owner